Loading…
The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives
Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the...
Saved in:
Published in: | Drug design, development and therapy development and therapy, 2023-01, Vol.17, p.2691-2725 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003 |
---|---|
cites | cdi_FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003 |
container_end_page | 2725 |
container_issue | |
container_start_page | 2691 |
container_title | Drug design, development and therapy |
container_volume | 17 |
creator | Niazi, Sarfaraz K |
description | Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the U.S. Food and Drug Administration (FDA) received over 100 product registration submissions that heavily relied on AI/ML for applications such as monitoring and improving human performance in compiling dossiers. To ensure the safe and effective use of AI/ML in drug discovery and manufacturing, the FDA and numerous other U.S. federal agencies have issued continuously updated, stringent guidelines. Intriguingly, these guidelines are often generated or updated with the aid of AI/ML tools themselves. The overarching goal is to expedite drug discovery, enhance the safety profiles of existing drugs, introduce novel treatment modalities, and improve manufacturing compliance and robustness. Recent FDA publications offer an encouraging outlook on the potential of these tools, emphasizing the need for their careful deployment. This has expanded market opportunities for retraining personnel handling these technologies and enabled innovative applications in emerging therapies such as gene editing, CRISPR-Cas9, CAR-T cells, mRNA-based treatments, and personalized medicine. In summary, the maturation of AI/ML technologies is a testament to human ingenuity. Far from being autonomous entities, these are tools created by and for humans designed to solve complex problems now and in the future. This paper aims to present the status of these technologies, along with examples of their present and future applications. |
doi_str_mv | 10.2147/DDDT.S424991 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d8f1afddb3ad46d2ae7f47d3cc14c10c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A770283485</galeid><doaj_id>oai_doaj_org_article_d8f1afddb3ad46d2ae7f47d3cc14c10c</doaj_id><sourcerecordid>A770283485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003</originalsourceid><addsrcrecordid>eNptksFr2zAUh83YWLtut52HYDB2SFLJkiN7lxHidSukbLDsLGTpyVGxpVSyA_3vpzRZSWDoIOn5ex_2zy_L3hM8ywnj13Vdr2e_Wc6qirzILgnhfFqWJXl5cr7I3sR4j_GcznP8OrugnGOCWXmZDesNoKXvrWuRN2jRwtN2e323QtahOowtqm1UfgfhcYJq2EHntz24YYKWnXVWyQ6tIQ5JMEHSaXQn3WikGsaQSl_Q3n9TL9AvCHELarA7iG-zV0Z2Ed4d96vsz8239fLHdPXz--1ysZqqglXDVCoKjGFWAS9I0eS0KnjBWLpBRUxZ6UIypXPWmIpzqYu8aACbFERDc0IxplfZ7cGrvbwX22B7GR6Fl1Y8FXxohQyDVR0IXRoijdYNlZrNdS6BG8Y1VYowRbBKrq8H13ZsetAqJRBkdyY9f-LsRrR-J1LOFSUFTYbPR0PwD2OKTPQpWOg66cCPUeTlnM1JiTlP6McD2sr0btYZn5Rqj4tF-nV5SVlZJGr2HyotDb1V3oGxqX7W8OmkYQOyGzbRd-NgvYvn4OQAquBjDGCev5NgsZ86sZ86cZy6hH84zeYZ_jdm9C-Rdc-f</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2864618077</pqid></control><display><type>article</type><title>The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives</title><source>Taylor & Francis_OA刊</source><source>NCBI_PubMed Central(免费)</source><source>Publicly Available Content (ProQuest)</source><creator>Niazi, Sarfaraz K</creator><creatorcontrib>Niazi, Sarfaraz K</creatorcontrib><description>Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the U.S. Food and Drug Administration (FDA) received over 100 product registration submissions that heavily relied on AI/ML for applications such as monitoring and improving human performance in compiling dossiers. To ensure the safe and effective use of AI/ML in drug discovery and manufacturing, the FDA and numerous other U.S. federal agencies have issued continuously updated, stringent guidelines. Intriguingly, these guidelines are often generated or updated with the aid of AI/ML tools themselves. The overarching goal is to expedite drug discovery, enhance the safety profiles of existing drugs, introduce novel treatment modalities, and improve manufacturing compliance and robustness. Recent FDA publications offer an encouraging outlook on the potential of these tools, emphasizing the need for their careful deployment. This has expanded market opportunities for retraining personnel handling these technologies and enabled innovative applications in emerging therapies such as gene editing, CRISPR-Cas9, CAR-T cells, mRNA-based treatments, and personalized medicine. In summary, the maturation of AI/ML technologies is a testament to human ingenuity. Far from being autonomous entities, these are tools created by and for humans designed to solve complex problems now and in the future. This paper aims to present the status of these technologies, along with examples of their present and future applications.</description><identifier>ISSN: 1177-8881</identifier><identifier>EISSN: 1177-8881</identifier><identifier>DOI: 10.2147/DDDT.S424991</identifier><identifier>PMID: 37701048</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>advanced manufacturing ; Artificial Intelligence ; drug development ; Drug Discovery ; Drugs ; fda ; Forecasts and trends ; Homeopathy ; Humans ; Machine Learning ; Materia medica and therapeutics ; Precision Medicine ; T cells ; Therapeutics ; United States ; United States Food and Drug Administration</subject><ispartof>Drug design, development and therapy, 2023-01, Vol.17, p.2691-2725</ispartof><rights>2023 Niazi.</rights><rights>COPYRIGHT 2023 Dove Medical Press Limited</rights><rights>2023 Niazi. 2023 Niazi.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003</citedby><cites>FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003</cites><orcidid>0000-0002-0513-0336</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493153/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493153/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37701048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niazi, Sarfaraz K</creatorcontrib><title>The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives</title><title>Drug design, development and therapy</title><addtitle>Drug Des Devel Ther</addtitle><description>Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the U.S. Food and Drug Administration (FDA) received over 100 product registration submissions that heavily relied on AI/ML for applications such as monitoring and improving human performance in compiling dossiers. To ensure the safe and effective use of AI/ML in drug discovery and manufacturing, the FDA and numerous other U.S. federal agencies have issued continuously updated, stringent guidelines. Intriguingly, these guidelines are often generated or updated with the aid of AI/ML tools themselves. The overarching goal is to expedite drug discovery, enhance the safety profiles of existing drugs, introduce novel treatment modalities, and improve manufacturing compliance and robustness. Recent FDA publications offer an encouraging outlook on the potential of these tools, emphasizing the need for their careful deployment. This has expanded market opportunities for retraining personnel handling these technologies and enabled innovative applications in emerging therapies such as gene editing, CRISPR-Cas9, CAR-T cells, mRNA-based treatments, and personalized medicine. In summary, the maturation of AI/ML technologies is a testament to human ingenuity. Far from being autonomous entities, these are tools created by and for humans designed to solve complex problems now and in the future. This paper aims to present the status of these technologies, along with examples of their present and future applications.</description><subject>advanced manufacturing</subject><subject>Artificial Intelligence</subject><subject>drug development</subject><subject>Drug Discovery</subject><subject>Drugs</subject><subject>fda</subject><subject>Forecasts and trends</subject><subject>Homeopathy</subject><subject>Humans</subject><subject>Machine Learning</subject><subject>Materia medica and therapeutics</subject><subject>Precision Medicine</subject><subject>T cells</subject><subject>Therapeutics</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1177-8881</issn><issn>1177-8881</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptksFr2zAUh83YWLtut52HYDB2SFLJkiN7lxHidSukbLDsLGTpyVGxpVSyA_3vpzRZSWDoIOn5ex_2zy_L3hM8ywnj13Vdr2e_Wc6qirzILgnhfFqWJXl5cr7I3sR4j_GcznP8OrugnGOCWXmZDesNoKXvrWuRN2jRwtN2e323QtahOowtqm1UfgfhcYJq2EHntz24YYKWnXVWyQ6tIQ5JMEHSaXQn3WikGsaQSl_Q3n9TL9AvCHELarA7iG-zV0Z2Ed4d96vsz8239fLHdPXz--1ysZqqglXDVCoKjGFWAS9I0eS0KnjBWLpBRUxZ6UIypXPWmIpzqYu8aACbFERDc0IxplfZ7cGrvbwX22B7GR6Fl1Y8FXxohQyDVR0IXRoijdYNlZrNdS6BG8Y1VYowRbBKrq8H13ZsetAqJRBkdyY9f-LsRrR-J1LOFSUFTYbPR0PwD2OKTPQpWOg66cCPUeTlnM1JiTlP6McD2sr0btYZn5Rqj4tF-nV5SVlZJGr2HyotDb1V3oGxqX7W8OmkYQOyGzbRd-NgvYvn4OQAquBjDGCev5NgsZ86sZ86cZy6hH84zeYZ_jdm9C-Rdc-f</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Niazi, Sarfaraz K</creator><general>Dove Medical Press Limited</general><general>Dove</general><general>Dove Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0513-0336</orcidid></search><sort><creationdate>20230101</creationdate><title>The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives</title><author>Niazi, Sarfaraz K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>advanced manufacturing</topic><topic>Artificial Intelligence</topic><topic>drug development</topic><topic>Drug Discovery</topic><topic>Drugs</topic><topic>fda</topic><topic>Forecasts and trends</topic><topic>Homeopathy</topic><topic>Humans</topic><topic>Machine Learning</topic><topic>Materia medica and therapeutics</topic><topic>Precision Medicine</topic><topic>T cells</topic><topic>Therapeutics</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niazi, Sarfaraz K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Drug design, development and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niazi, Sarfaraz K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives</atitle><jtitle>Drug design, development and therapy</jtitle><addtitle>Drug Des Devel Ther</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>17</volume><spage>2691</spage><epage>2725</epage><pages>2691-2725</pages><issn>1177-8881</issn><eissn>1177-8881</eissn><abstract>Artificial intelligence (AI) and machine learning (ML) represent significant advancements in computing, building on technologies that humanity has developed over millions of years-from the abacus to quantum computers. These tools have reached a pivotal moment in their development. In 2021 alone, the U.S. Food and Drug Administration (FDA) received over 100 product registration submissions that heavily relied on AI/ML for applications such as monitoring and improving human performance in compiling dossiers. To ensure the safe and effective use of AI/ML in drug discovery and manufacturing, the FDA and numerous other U.S. federal agencies have issued continuously updated, stringent guidelines. Intriguingly, these guidelines are often generated or updated with the aid of AI/ML tools themselves. The overarching goal is to expedite drug discovery, enhance the safety profiles of existing drugs, introduce novel treatment modalities, and improve manufacturing compliance and robustness. Recent FDA publications offer an encouraging outlook on the potential of these tools, emphasizing the need for their careful deployment. This has expanded market opportunities for retraining personnel handling these technologies and enabled innovative applications in emerging therapies such as gene editing, CRISPR-Cas9, CAR-T cells, mRNA-based treatments, and personalized medicine. In summary, the maturation of AI/ML technologies is a testament to human ingenuity. Far from being autonomous entities, these are tools created by and for humans designed to solve complex problems now and in the future. This paper aims to present the status of these technologies, along with examples of their present and future applications.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>37701048</pmid><doi>10.2147/DDDT.S424991</doi><tpages>35</tpages><orcidid>https://orcid.org/0000-0002-0513-0336</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1177-8881 |
ispartof | Drug design, development and therapy, 2023-01, Vol.17, p.2691-2725 |
issn | 1177-8881 1177-8881 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_d8f1afddb3ad46d2ae7f47d3cc14c10c |
source | Taylor & Francis_OA刊; NCBI_PubMed Central(免费); Publicly Available Content (ProQuest) |
subjects | advanced manufacturing Artificial Intelligence drug development Drug Discovery Drugs fda Forecasts and trends Homeopathy Humans Machine Learning Materia medica and therapeutics Precision Medicine T cells Therapeutics United States United States Food and Drug Administration |
title | The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A37%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Coming%20of%20Age%20of%20AI/ML%20in%20Drug%20Discovery,%20Development,%20Clinical%20Testing,%20and%20Manufacturing:%20The%20FDA%20Perspectives&rft.jtitle=Drug%20design,%20development%20and%20therapy&rft.au=Niazi,%20Sarfaraz%20K&rft.date=2023-01-01&rft.volume=17&rft.spage=2691&rft.epage=2725&rft.pages=2691-2725&rft.issn=1177-8881&rft.eissn=1177-8881&rft_id=info:doi/10.2147/DDDT.S424991&rft_dat=%3Cgale_doaj_%3EA770283485%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c549t-ac3e44049e7515b23957544e75e91f89d5a4cd24bf977ad525be0f249b3213003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2864618077&rft_id=info:pmid/37701048&rft_galeid=A770283485&rfr_iscdi=true |